The overall goal of this academic-industrial partnership between researchers at Johns Hopkins University and Philips Healthcare/Philips Research is to develop and optimize the novel amide proton transfer (APT) imaging technique for efficient and reliable detection of malignant brain tumors and assessment of treatment response. APT imaging can provide endogenous contrast related to mobile protein content in tissue. Preclinical studies and clinical data suggest that APT imaging may provide unique information about the presence and grade of brain tumors, as revealed by MRI-guided proteomics and in vivo MR spectroscopy. Notably, we recently demonstrated in animal models that the APT-MRI signal is a unique imaging biomarker to distinguish between radiation necrosis and active tumor tissue. Similar to other MRI techniques, the ultimate goal for APT imaging is the standardized use in a clinical setting. However, current APT imaging protocols are far from being optimized. A main reason is that the APT experimental parameters are often limited by scanner hardware constraints, particularly with respect to amplifier duty-cycle and specific absorption rate requirements. In addition to pulse sequence parameter differences, leading to inconsistent effect sizes, data processing strategies vary and may affect the reproducibility of results between hospitals. Therefore, there is an urgent need for industry and academia to work together to develop this emerging technology into a clinically viable, easy-to-use, and reproducible approach. To accomplish this, we (researchers at JHU and Philips) agreed to establish a cooperation to achieve an accelerated APT translation. Together, we formulated the following two specific aims: (1) Optimize and standardize APT imaging technology on 3T human MRI systems; and (2) Test the methodologies developed in Aim 1 on patients with brain tumors. APT imaging has the potential to introduce an entirely new molecular MRI methodology into the clinic that can detect endogenous cellular protein signals in biological tissue non-invasively. Thi research will provide the standard optimized approaches required to translate this new technology into the clinic.

Public Health Relevance

The overall goal of this academic-industrial partnership is to optimize a novel MR molecular imaging technique, called amide proton transfer imaging, for efficient and reliable detection of malignant brain tumors on 3T human MRI scanners. If successful, we expect to provide an entirely new and optimized whole-brain imaging technology that can reliably identify the spatial extent of high grade tumors non-invasively, for both contras-enhancing and non-enhancing gliomas. This specific MRI modality is expected to aid in the diagnosis and treatment of brain tumors, directly impacting patient care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-SBIB-X (57))
Program Officer
Zhang, Huiming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Jiang, Shanshan; Yu, Hao; Wang, Xianlong et al. (2016) Molecular MRI differentiation between primary central nervous system lymphomas and high-grade gliomas using endogenous protein-based amide proton transfer MR imaging at 3 Tesla. Eur Radiol 26:64-71
Zhang, Yi; Heo, Hye-Young; Lee, Dong-Hoon et al. (2016) Selecting the reference image for registration of CEST series. J Magn Reson Imaging 43:756-61
Heo, Hye-Young; Lee, Dong-Hoon; Zhang, Yi et al. (2016) Insight into the quantitative metrics of chemical exchange saturation transfer (CEST) imaging. Magn Reson Med :
Ma, Bo; Blakeley, Jaishri O; Hong, Xiaohua et al. (2016) Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging 44:456-62
Lee, Dong-Hoon; Heo, Hye-Young; Zhang, Kai et al. (2016) Quantitative assessment of the effects of water proton concentration and water T1 changes on amide proton transfer (APT) and nuclear overhauser enhancement (NOE) MRI: The origin of the APT imaging signal in brain tumor. Magn Reson Med :
Heo, Hye-Young; Zhang, Yi; Jiang, Shanshan et al. (2016) Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semisolid magnetization transfer reference (EMR) signals: II. Comparison of three EMR models and application to human brain glioma at Magn Reson Med 75:1630-9
Yu, Yang; Lee, Dong-Hoon; Peng, Shin-Lei et al. (2016) Assessment of Glioma Response to Radiotherapy Using Multiple MRI Biomarkers with Manual and Semiautomated Segmentation Algorithms. J Neuroimaging 26:626-634
Deng, Min; Chen, Shu-Zhong; Yuan, Jing et al. (2016) Chemical Exchange Saturation Transfer (CEST) MR Technique for Liver Imaging at 3.0 Tesla: an Evaluation of Different Offset Number and an After-Meal and Over-Night-Fast Comparison. Mol Imaging Biol 18:274-82
Heo, Hye-Young; Zhang, Yi; Lee, Dong-Hoon et al. (2016) Accelerating chemical exchange saturation transfer (CEST) MRI by combining compressed sensing and sensitivity encoding techniques. Magn Reson Med :
Zhang, Yi; Heo, Hye-Young; Lee, Dong-Hoon et al. (2016) Chemical exchange saturation transfer (CEST) imaging with fast variably-accelerated sensitivity encoding (vSENSE). Magn Reson Med :

Showing the most recent 10 out of 30 publications